FY2024 EPS Estimates for Eyenovia Raised by William Blair

Eyenovia, Inc. (NASDAQ:EYEN) – Research analysts at William Blair raised their FY2024 EPS estimates for Eyenovia in a note issued to investors on Wednesday, November 13th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($0.47) per share for the year, up from their prior forecast of ($0.53). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.50) per share. William Blair also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.37) EPS.

EYEN has been the topic of a number of other reports. Brookline Capital Management reissued a “hold” rating on shares of Eyenovia in a research note on Friday. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Eyenovia in a research report on Wednesday, November 13th.

Eyenovia Price Performance

Shares of NASDAQ:EYEN opened at $0.10 on Monday. The company has a market cap of $6.53 million, a P/E ratio of -0.14 and a beta of 1.75. The business has a fifty day simple moving average of $0.49 and a 200-day simple moving average of $0.71. Eyenovia has a 52 week low of $0.09 and a 52 week high of $2.57. The company has a quick ratio of 0.27, a current ratio of 0.74 and a debt-to-equity ratio of 0.58.

Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period in the prior year, the firm posted ($0.18) earnings per share.

Insider Transactions at Eyenovia

In other news, CEO Michael M. Rowe purchased 50,000 shares of the stock in a transaction on Monday, August 26th. The stock was purchased at an average price of $0.57 per share, with a total value of $28,500.00. Following the completion of the transaction, the chief executive officer now owns 82,927 shares in the company, valued at approximately $47,268.39. The trade was a 151.85 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.10% of the company’s stock.

Hedge Funds Weigh In On Eyenovia

Several hedge funds and other institutional investors have recently modified their holdings of EYEN. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eyenovia in the second quarter valued at approximately $26,000. Ground Swell Capital LLC purchased a new position in shares of Eyenovia in the 2nd quarter valued at $27,000. Nations Financial Group Inc. IA ADV lifted its holdings in shares of Eyenovia by 24.4% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock valued at $30,000 after acquiring an additional 10,000 shares in the last quarter. Financial Management Network Inc. purchased a new stake in Eyenovia during the 3rd quarter worth $39,000. Finally, SkyView Investment Advisors LLC acquired a new stake in Eyenovia in the 2nd quarter valued at $87,000. 25.84% of the stock is owned by institutional investors and hedge funds.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.